Membranous nephropathy preceding Bing-Neel syndrome: successful treatment with tirabrutinib
Journal of Nephrology · 2025
DOI: 10.1007/s40620-025-02401-7 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Nephrology, 2025. Verfasst von Kanako Watanabe-Kusunoki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. w…. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Waldenstrom Macroglobulinemia, Protein Kinase Inhibitors, Pyrimidines. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
We report a unique case of membranous nephropathy and tubulointerstitial nephritis preceding neurological manifestations of Bing-Neel syndrome, a rare variant of Waldenström macroglobulinemia. A 46-year-old man presented with nephrotic syndrome, and kidney biopsy revealed membranous nephropathy with phospholipase A2 receptor positivity and IgG4 predominance. Despite initial partial remission with corticosteroids and cyclosporine, neurological symptoms emerged alongside nephrotic syndrome relapse two years after onset. Diagnostic workup revealed serum monoclonal IgM kappa, abnormal lymphoplasmacytic cells in bone marrow and cerebrospinal fluid, and MYD88 L265P mutation in the latter, confirming Bing-Neel syndrome. Immunostaining of the initial kidney biopsy demonstrated IgM-kappa-positive lymphoplasmacytic infiltration consistent with the monoclonal protein. After bendamustine-rituximab therapy showed partial effectiveness, tirabrutinib, a Bruton tyrosine kinase inhibitor, achieved complete remission of both renal and neurological manifestations with sustained response over three years. Immunofluorescence staining revealed increased nuclear factor (NF)-κB and STAT3 expression in infiltrating immune cells and elevated NF-κB in surrounding tubular epithelial cells, suggesting activation of these pathways downstream of the MYD88 mutation in kidney pathology. Our findings suggest a potential contribution of Bruton's tyrosine kinase signaling to both kidney and neurological pathology in Bing-Neel syndrome, with tirabrutinib achieving clinical improvement in both organ manifestations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. watakana@med.hokudai.ac.jp.
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
- Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
- Department of Pathology, Sapporo City General Hospital, Sapporo, Japan.
Zitieren
APA
Watanabe-Kusunoki, K., Nakazawa, D., Ohigashi, H., Tsuji, T., & Atsumi, T. (2025). Membranous nephropathy preceding Bing-Neel syndrome: successful treatment with tirabrutinib. Journal of Nephrology. https://doi.org/10.1007/s40620-025-02401-7
Vancouver
Watanabe-Kusunoki K, Nakazawa D, Ohigashi H, Tsuji T, Atsumi T. Membranous nephropathy preceding Bing-Neel syndrome: successful treatment with tirabrutinib. Journal of Nephrology. 2025. doi:10.1007/s40620-025-02401-7
BibTeX
@article{WatanabeKusunoki2025,
author = {Watanabe-Kusunoki, Kanako and Nakazawa, Daigo and Ohigashi, Hiroyuki and Tsuji, Takahiro and Atsumi, Tatsuya},
title = {Membranous nephropathy preceding Bing-Neel syndrome: successful treatment with tirabrutinib},
journal = {Journal of Nephrology},
year = {2025},
doi = {10.1007/s40620-025-02401-7}
}
EUVIMED